Our Work

Our work is inseparable from the quality of our science

At Compass, a rigorous, relentless pursuit of evidence grounds every discovery, because that’s precisely what’s required to move medicine forward.

We’re pursuing a greater understanding of how classic psychedelics affect the brain’s ability to communicate across regions—specifically how it influences the way we perceive ourselves and interact with the world. This mechanism is thought to create a “window of opportunity” for change, providing the potential to transform entrenched thought patterns or behaviors.

By the numbers

Our research and development has spanned a decade, and in that time, we’ve built the world’s largest classic psychedelic clinical program, aiming to prove psilocybin belongs in mainstream medicine.

1450+
participants across all our trials.
14
trials completed or ongoing.
125+
research sites around the world.
13
countries participating in this essential research.

Treatment-resistant depression (TRD)

TRD is more than a diagnosis; it’s the churning cycle of inadequate responses to treatments that often leave individuals without relief. We are dedicated to those for whom depression has repeatedly resisted treatment, facing longer depressive episodes, higher risks and diminished quality of life¹ and for whom science needs to rigorously pursue new possibilities.

Post-traumatic stress disorder (PTSD)

PTSD is a condition that may occur in people who have experienced traumatic events,² from combat or assault to accidents or natural disasters. This constant state of high alert often complicates life with intense comorbid distress. We are committed to these individuals, whose lives have been obscured by the devastation of PTSD and seek a path through it.

See our clinical trials

We encourage you to visit clinicaltrials.gov to learn more about our clinical trials.

Go to clinicaltrials.gov

Continue exploring

Learn more